Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: A sonotrode (18) for producing a welded and/or soldered join between a cable (17) and a sheath (17), covering the cable (17), comprising at least one working surface (2). The working surface (2) is curved in a concave manner, at least in sections. An anvil (10) comprises at least one counter surface (11) which is curved in a concave manner, at least in sections. The device for producing the join between a cable (17) and a sheath (17), covering the cable (17), comprises a sonotrode (18) joined to an ultrasound source (8) at least at a joining surface (5), and comprising an anvil (10) arranged opposite the working surface (2) of the sonotrode (18). A method for producing a join between a cable (17) and a sheath (17) covering the cable (17) is also disclosed.

Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: A DC voltage source, for example an AC/DC converter, has an output producing a controllable DC voltage for a DC charging station to charge the battery of an electric vehicle. A voltage balancing unit is connected between the output of the converter and the output terminal of the DC charging station. The voltage balancing unit has a controllable switch by which the connection between voltage source or converter and battery can be made or broken as desired. The switch is controlled as a function of the voltage on the input and output side of the voltage balancing unit to the effect that the switch breaks the connection before and while the battery is being connected to the DC output terminal, and makes a connection only when the voltage on the input side of the voltage balancing unit corresponds substantially to the voltage on the output side of the voltage balancing unit.

Abstract: A pharmaceutical combination comprising (a) the phosphatidylinositol 3-kinase (PI3K) inhibitor compound (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]thiazol-2-yl}-amide) or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Abstract: The present invention relates to the utilization of one or more genes selected from the group comprising ZFP64, DPP3, CCDC43, HIST2H4A/B, KDELC2 and MICALL1 as biomarkers for HDAC inhibitor treatment. The expression and/or change of the aforementioned genes are preferably determined via the respective corresponding mRNA or one or more proteins expressed by the aforementioned genes.

Abstract: Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: In one embodiment, the present invention includes a computer-implemented method comprising monitoring a first condition of an in-memory database. An in-memory data store stores an in-memory database. The method further comprises determining whether the first condition of the in-memory database meets a first defined criterion. If the first condition of the in-memory database meets the first defined criterion, the in-memory database is stored in a persistent data store as a storage based database. If a received query is a query of the storage based database, the query is executed using the storage based database. Metadata of the in-memory database is mapped into a metadata repository if the in-memory database is stored in the in-memory data store. Metadata of the in-memory database is remapped in the metadata repository if the in-memory database is stored in the persistent data store as the storage based database.

Abstract: A method is disclosed for charging at least one energy store of an electric vehicle via a charging point, using a first terminal having first connecting elements of a charging cable connected to the charging point. The first connecting elements are connected to corresponding second connecting elements of a second terminal on the vehicle, and the first and second connecting elements are designed to supply alternating current for charging the at least one energy store. Direct current from the charging point for charging the at least one energy store is supplied to the electric vehicle via at least two first connecting elements or at least two third connecting elements of the first terminal, wherein PLC communication between the electric vehicle and charging point in order to exchange information relating to the charging operation occurs via one or more first connecting elements on which no direct current for charging is carried.

Abstract: The present invention is related to the tripeptide (I)Lys-(d)Pro-(I)Thr (KdPT) or pharmaceutically acceptable salts thereof for therapeutic, prophylactic therapeutic or cosmetic treatment of a disease with increased apoptosis, wherein the treatment has an anti-apoptotic effect. The present invention is also related to the use of KdPT or pharmaceutically acceptable salts thereof for the manufacture of a pharmaceutical or cosmetic composition for an anti-apoptotic treatment of disorders that are related with increased apoptosis.

Abstract: Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: The present invention is related to the tripeptide (I)Lys-(d)Pro-(I)Thr (KdPT) or pharmaceutically acceptable salts thereof for therapeutic, prophylactic therapeutic or cosmetic treatment of a disease with increased apoptosis, wherein the treatment has an anti-apoptotic effect. The present invention is also related to the use of KdPT or pharmaceutically acceptable salts thereof for the manufacture of a pharmaceutical or cosmetic composition for an anti-apoptotic treatment of disorders that are related with increased apoptosis.

Abstract: Disclosed herein are system, method, and computer program product embodiments for data replication for cloud based in-memory databases. An embodiment operates by requesting, by a first computing device, configuration of an on-demand cloud-based in-memory database, assessing, at the first computing device, database system components, and transmitting database system component information from the first computing device to a second computing device over a network. The first computing device receives from the second computing device an evaluation of the database system components and a recommended replication strategy responsive to a replication rule set. The database system components at the first computing device are then configured to use the recommended replication strategy.

Abstract: A pharmaceutical combination comprising (a) the phosphatidylinositol 3-kinase (PI3K) inhibitor compound (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Abstract: In one embodiment, the present invention includes a computer-implemented method comprising monitoring a first condition of an in-memory database. An in-memory data store stores an in-memory database. The method further comprises determining whether the first condition of the in-memory database meets a first defined criterion. If the first condition of the in-memory database meets the first defined criterion, the in-memory database is stored in a persistent data store as a storage based database. If a received query is a query of the storage based database, the query is executed using the storage based database. Metadata of the in-memory database is mapped into a metadata repository if the in-memory database is stored in the in-memory data store. Metadata of the in-memory database is remapped in the metadata repository if the in-memory database is stored in the persistent data store as the storage based database.

Abstract: A method is disclosed for charging at least one energy store of an electric vehicle via a charging point, using a first terminal having first connecting elements of a charging cable connected to the charging point. The first connecting elements are connected to corresponding second connecting elements of a second terminal on the vehicle, and the first and second connecting elements are designed to supply alternating current for charging the at least one energy store. Direct current from the charging point for charging the at least one energy store is supplied to the electric vehicle via at least two first connecting elements or at least two third connecting elements of the first terminal, wherein PLC communication between the electric vehicle and charging point in order to exchange information relating to the charging operation occurs via one or more first connecting elements on which no direct current for charging is carried.

Abstract: The present invention relates to the use of one or more tripeptides selected from the group consisting of NLys-Pro-ValC, NLys-Pro-ThrC and NpGlu-His-ProC for the reduction of oxidative stress. The above tripeptides are particularly useful for the treatment of a disease or damage caused by oxidative stress; such as vitiligo, scleroderma, necrosis, or erythema; furthermore, a disease or damage of the hair, like premature hair loss or premature formation of grey hair. Furthermore the invention relates the cosmetic use of the above tripeptides, in particular against skin aging. Further the invention relates cosmetic compositions containing at least one of said tripeptides.

Abstract: A DC voltage source, for example an AC/DC converter, has an output producing a controllable DC voltage for a DC charging station to charge the battery of an electric vehicle. A voltage balancing unit is connected between the output of the converter and the output terminal of the DC charging station. The voltage balancing unit has a controllable switch by which the connection between voltage source or converter and battery can be made or broken as desired. The switch is controlled as a function of the voltage on the input and output side of the voltage balancing unit to the effect that the switch breaks the connection before and while the battery is being connected to the DC output terminal, and makes a connection only when the voltage on the input side of the voltage balancing unit corresponds substantially to the voltage on the output side of the voltage balancing unit.

Abstract: In an embodiment of the invention, analytical data may be extracted from a business intelligence (BI) system on criteria specified in metadata of a business intelligence query. Once the data is extracted from the BI system, the extracted content may be provided in the context of semantic identifiers. In an embodiment, the semantic identifiers may provide a description of the extracted content associated with the identifier. In one embodiment, the semantic identifiers may be obtained from the criteria specified in the query. In another embodiment, the semantic identifiers may be defined in and obtained from a separate enterprise service repository. In an embodiment, a proposed mapping between query elements and semantic identifiers may be suggested by a processor.